Dwadzieścia powodów, dla których warto stosować zofenopryl Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
mar 31, 2014
Słowa kluczowe:
zofenopryl, układ sercowo-naczyniowy
##plugins.themes.bootstrap3.article.main##
Abstrakt
Zofenopryl należy do lipofilnych inhibitorów konwertazy i zawiera grupę sulfhydrylową w cząsteczce. Udowodniono, że w porównaniu z innymi inhibitorami konwertazy ma on dużą aktywność tkankową w hamowaniu enzymu konwertującego. Efekt ten utrzymuje się szczególnie długo w mięśniu sercowym i łożysku naczyniowym. Zofenopryl wywołuje wiele korzystnych działań, które wymieniono w kolejnych punktach. Wśród nich są: korzystny wpływ na funkcję śródbłonka, działanie przeciwzapalne, zwiększone lokalne wytwarzanie tlenku azotu i hamowanie metabolicznych oraz hemodynamicznych skutków niedokrwienia mięśnia sercowego. Skuteczność leku potwierdzono w badaniach u wielu grup chorych.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Abramczyk , P., & Lewandowski , J. (2014). Dwadzieścia powodów, dla których warto stosować zofenopryl . Medycyna Faktów , 7(1(22), 32-38. Pobrano z https://www.journalsmededu.pl/index.php/jebm/article/view/2380
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Ranadive S.A., Chen A.X., Serajuddin A.T.M.: Relative lipophilicities and structural-pharmacological considerations of various angiotensinconverting enzyme (ACE) inhibitors. Pharm. Res. 1992; 9: 1480-1486.
2. Cushman D.W., Wang F.L., Fung W.C. et al.: Comparisons “in vitro”, “ex vivo”, and “in vivo” of the actions of seven structurally diverse inhibitors of angiotensin converting enzyme (ACE). Br. J. Clin. Pharmacol. 1989; 28: 115S-131S.
3. Cushman D.W., Wang F.L., Fung W.C. et al.: Differentiation of angiotensin-converting enzyme (ACE) inhibitors by their selective inhibition of ACE in physiologically important target organs. Am. J. Hypert. 1989; 2: 294-306.
4. Grover G.J., Sleph P.G., Dzwonczyk S. et al.: Effects of different angiotensin-converting enzyme (ACE) inhibitors on ischemic isolated rat hearts: Relationship between cardiac ACE inhibitor and cardioprotection. J. Pharmacol. Exp. Ther. 1991; 257: 919-929.
5. Subissi A., Evangelista S., Giachetti A.: Preclinical Profile of Zofenopril: An Angiotensin Converting Enzyme Inhibitor with Peculiar Cardioprotective Properties. Cardiovasc. Drug. Rev. 1999; 17(2): 115-133.
6. DeForrest J.M., Waldron T.L., Krapcho J. et al.: Preclinical pharmacology of zofenopril, an inhibitor of angiotensin I converting enzyme. J. Cardiovasc. Pharmacol. 1989; 13: 887-894.
7. Mitchell G.F., Pfeffer M.A., Finn P.V. et al.: Equipotent antihypertensive agents variously affect pulsatile hemodynamics and regression of cardiac hypertrophy in spontaneously hypertensive rats. Circulation 1996; 94: 2923-2929.
8. Farsang C.: Blood pressure control and response rates with zofenopril compared with amlodipine in hypertensive patients. Blood Press. Suppl. 2007; 2: 19-24.
9. Narkiewicz K.: Comparison of home and office blood pressure in hypertensive patients treated with zofenopril or losartan. Blood Press. Suppl. 2007; 2: 7-12.
10. Mallion J.M.: An evaluation of the initial and long-term antihypertensive efficacy of zofenopril compared with enalapril in mild to moderate hypertension. Blood Press. Suppl. 2007; 2: 13-18.
11. Farsang C.: Blood pressure control and response rates with zofenopril compared with amlodipine in hypertensive patients. Blood Press. Suppl. 2007; 2: 19-24.
12. Nilsson P.: Antihypertensive efficacy of zofenopril compared with atenolol in patients with mild to moderate hypertension. Blood Press. Suppl. 2007; 2: 25-30.
13. Ambrosioni E., Borghi C., Magnani B.: The Effect of the Angiotensin-Converting–Enzyme Inhibitor Zofenopril on Mortality and Morbidity after Anterior Myocardial Infarction. N. Engl. J. Med. 1995; 332: 80-85.
14. Borghi C., Ambrosioni E.: Survival of Myocardial Infarction Long-term Evaluation-2 Working Party. Double-blind comparison between zofenopril and lisinopril in patients with acute myocardial infarction: results of the Survival of Myocardial Infarction Long-term Evaluation-2 (SMILE- 2) study. Am. Heart J. 2003; 145(1): 80-87.
15. Borghi C., Ambrosioni E., Novo S. et al.; SMILE-4 Working Party: Comparison between zofenopril and ramipril in combination with acetylsalicylic acid in patients with left ventricular systolic dysfunction after acute myocardial infarction: results of a randomized, double-blind, parallel- group, multicenter, European study (SMILE-4). Clin. Cardiol. 2012; 35(7): 416-23.
16. Borghi C., Cicero A.F.: Fixed combination of zofenopril plus hydrochlorothiazide in the management of hypertension: a review of available data. Vasc. Health Risk Manag. 2006; 2(4): 341-9.
17. Brilla C.G.: Regression of myocardial fibrosis in hypertensive heart disease: diverse effects of various antihypertensive drugs. Cardiovasc. Res. 2000; 46(2): 324-31.
18. van Gilst W.H., de Graeff P.A., de Leeue M.J. et al.: Converting enzyme inhibitors and the role of the sulfhydryl group in the potentiation of exo- and endogenous nitrovasodilatators. J. Cardiovasc. Pharmacol. 1991; 18: 429-436.
19. van Gilst W.H., Scholtens E., de Graeff P.A. et al.: Differential influences of angiotensin converting-enzyme inhibitors on the coronary circulation. Circulation 1988; 77(Suppl. 1): 24-29.
20. Liu X., Engelman R.M., Ronson J.A. et al.: Attenuation of myocardial reperfusion injury by sulfhydryl-containing angiotensin converting enzyme inhibitors. Cardiovasc. Drugs Ther. 1992; 6: 437-443.
21. Cominacini L., Pasini A., Garbin U. et al.: Zofenopril inhibits the expression of adhesion molecules on endothelial cells by reducing reactive oxygen species. Am. J. Hypertens. 2002; 15: 891-895.
22. Napoli C., Sica V., de Nigris F. et al.: Sulfhydryl angiotensin-converting enzyme inhibition induces sustained reduction of systemic oxidative stress and improves the nitric oxide pathway in patients with essential hypertension. Am. Heart J. 2004; 148(1): e5.
23. Rizos E.C.: Improvement of the lipid profile with zofenopril In hypertensive patients with the metabolit syndrome. The Open Clin. Chemistry J. 2008; 1: 64-68.
24. Grover G.J., Sleph P.G., Dzwonczyk S. et al.: Effects of different angiotensin-converting enzyme (ACE) inhibitors on ischemic isolated rat hearts: Relationship between cardiac ACE inhibitor and cardioprotection. J. Pharmacol. Exp. Ther. 1991; 257: 919-929.
25. Ferrari R., Cargnoni S., Curello C. et al.: Protection of the ischemic myocardium by the converting-enzyme inhibitor zofenopril: Insight into its mechanism of action. J. Cardiovasc. Pharmacol. 1992; 20: 694-704.
26. Sargent C.A., Sleph P.G., Dzwonczyk S. et al.: Cardioprotection in ischemic rat hearts with the SH-containing angiotensin-converting enzyme inhibitor zofenopril: Possible involvement of the ATP-sensitive potassium channel. J. Pharmacol. Exp. Ther. 1993; 265: 609-618.
27. Dyrla W., Wsół A., Kuch M.: Czy kwas acetylosalicylowy rzeczywiście obniża skuteczność inhibitorów ACE po zawale serca? Medycyna Faktów 2012; 2(15): 12-18.
28. Borghi C., Ambrosioni E.: Survival of Myocardial Infarction Long-term Evaluation Study Group. Effects of zofenopril on myocardial ischemia in post-myocardial infarction patients with preserved left ventricular function: the Survival of Myocardial Infarction Long-term Evaluation (SMILE)-ISCHEMIA study. Am. Heart J. 2007; 153(3): 445.e7-14.
2. Cushman D.W., Wang F.L., Fung W.C. et al.: Comparisons “in vitro”, “ex vivo”, and “in vivo” of the actions of seven structurally diverse inhibitors of angiotensin converting enzyme (ACE). Br. J. Clin. Pharmacol. 1989; 28: 115S-131S.
3. Cushman D.W., Wang F.L., Fung W.C. et al.: Differentiation of angiotensin-converting enzyme (ACE) inhibitors by their selective inhibition of ACE in physiologically important target organs. Am. J. Hypert. 1989; 2: 294-306.
4. Grover G.J., Sleph P.G., Dzwonczyk S. et al.: Effects of different angiotensin-converting enzyme (ACE) inhibitors on ischemic isolated rat hearts: Relationship between cardiac ACE inhibitor and cardioprotection. J. Pharmacol. Exp. Ther. 1991; 257: 919-929.
5. Subissi A., Evangelista S., Giachetti A.: Preclinical Profile of Zofenopril: An Angiotensin Converting Enzyme Inhibitor with Peculiar Cardioprotective Properties. Cardiovasc. Drug. Rev. 1999; 17(2): 115-133.
6. DeForrest J.M., Waldron T.L., Krapcho J. et al.: Preclinical pharmacology of zofenopril, an inhibitor of angiotensin I converting enzyme. J. Cardiovasc. Pharmacol. 1989; 13: 887-894.
7. Mitchell G.F., Pfeffer M.A., Finn P.V. et al.: Equipotent antihypertensive agents variously affect pulsatile hemodynamics and regression of cardiac hypertrophy in spontaneously hypertensive rats. Circulation 1996; 94: 2923-2929.
8. Farsang C.: Blood pressure control and response rates with zofenopril compared with amlodipine in hypertensive patients. Blood Press. Suppl. 2007; 2: 19-24.
9. Narkiewicz K.: Comparison of home and office blood pressure in hypertensive patients treated with zofenopril or losartan. Blood Press. Suppl. 2007; 2: 7-12.
10. Mallion J.M.: An evaluation of the initial and long-term antihypertensive efficacy of zofenopril compared with enalapril in mild to moderate hypertension. Blood Press. Suppl. 2007; 2: 13-18.
11. Farsang C.: Blood pressure control and response rates with zofenopril compared with amlodipine in hypertensive patients. Blood Press. Suppl. 2007; 2: 19-24.
12. Nilsson P.: Antihypertensive efficacy of zofenopril compared with atenolol in patients with mild to moderate hypertension. Blood Press. Suppl. 2007; 2: 25-30.
13. Ambrosioni E., Borghi C., Magnani B.: The Effect of the Angiotensin-Converting–Enzyme Inhibitor Zofenopril on Mortality and Morbidity after Anterior Myocardial Infarction. N. Engl. J. Med. 1995; 332: 80-85.
14. Borghi C., Ambrosioni E.: Survival of Myocardial Infarction Long-term Evaluation-2 Working Party. Double-blind comparison between zofenopril and lisinopril in patients with acute myocardial infarction: results of the Survival of Myocardial Infarction Long-term Evaluation-2 (SMILE- 2) study. Am. Heart J. 2003; 145(1): 80-87.
15. Borghi C., Ambrosioni E., Novo S. et al.; SMILE-4 Working Party: Comparison between zofenopril and ramipril in combination with acetylsalicylic acid in patients with left ventricular systolic dysfunction after acute myocardial infarction: results of a randomized, double-blind, parallel- group, multicenter, European study (SMILE-4). Clin. Cardiol. 2012; 35(7): 416-23.
16. Borghi C., Cicero A.F.: Fixed combination of zofenopril plus hydrochlorothiazide in the management of hypertension: a review of available data. Vasc. Health Risk Manag. 2006; 2(4): 341-9.
17. Brilla C.G.: Regression of myocardial fibrosis in hypertensive heart disease: diverse effects of various antihypertensive drugs. Cardiovasc. Res. 2000; 46(2): 324-31.
18. van Gilst W.H., de Graeff P.A., de Leeue M.J. et al.: Converting enzyme inhibitors and the role of the sulfhydryl group in the potentiation of exo- and endogenous nitrovasodilatators. J. Cardiovasc. Pharmacol. 1991; 18: 429-436.
19. van Gilst W.H., Scholtens E., de Graeff P.A. et al.: Differential influences of angiotensin converting-enzyme inhibitors on the coronary circulation. Circulation 1988; 77(Suppl. 1): 24-29.
20. Liu X., Engelman R.M., Ronson J.A. et al.: Attenuation of myocardial reperfusion injury by sulfhydryl-containing angiotensin converting enzyme inhibitors. Cardiovasc. Drugs Ther. 1992; 6: 437-443.
21. Cominacini L., Pasini A., Garbin U. et al.: Zofenopril inhibits the expression of adhesion molecules on endothelial cells by reducing reactive oxygen species. Am. J. Hypertens. 2002; 15: 891-895.
22. Napoli C., Sica V., de Nigris F. et al.: Sulfhydryl angiotensin-converting enzyme inhibition induces sustained reduction of systemic oxidative stress and improves the nitric oxide pathway in patients with essential hypertension. Am. Heart J. 2004; 148(1): e5.
23. Rizos E.C.: Improvement of the lipid profile with zofenopril In hypertensive patients with the metabolit syndrome. The Open Clin. Chemistry J. 2008; 1: 64-68.
24. Grover G.J., Sleph P.G., Dzwonczyk S. et al.: Effects of different angiotensin-converting enzyme (ACE) inhibitors on ischemic isolated rat hearts: Relationship between cardiac ACE inhibitor and cardioprotection. J. Pharmacol. Exp. Ther. 1991; 257: 919-929.
25. Ferrari R., Cargnoni S., Curello C. et al.: Protection of the ischemic myocardium by the converting-enzyme inhibitor zofenopril: Insight into its mechanism of action. J. Cardiovasc. Pharmacol. 1992; 20: 694-704.
26. Sargent C.A., Sleph P.G., Dzwonczyk S. et al.: Cardioprotection in ischemic rat hearts with the SH-containing angiotensin-converting enzyme inhibitor zofenopril: Possible involvement of the ATP-sensitive potassium channel. J. Pharmacol. Exp. Ther. 1993; 265: 609-618.
27. Dyrla W., Wsół A., Kuch M.: Czy kwas acetylosalicylowy rzeczywiście obniża skuteczność inhibitorów ACE po zawale serca? Medycyna Faktów 2012; 2(15): 12-18.
28. Borghi C., Ambrosioni E.: Survival of Myocardial Infarction Long-term Evaluation Study Group. Effects of zofenopril on myocardial ischemia in post-myocardial infarction patients with preserved left ventricular function: the Survival of Myocardial Infarction Long-term Evaluation (SMILE)-ISCHEMIA study. Am. Heart J. 2007; 153(3): 445.e7-14.